{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:55:00Z","timestamp":1787165700212,"version":"build-2736575974"},"reference-count":35,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2025.0159","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:25:56Z","timestamp":1768548356000},"source":"Crossref","is-referenced-by-count":2,"title":["Gastric carcinoma\u2014diagnosis, staging, and treatment"],"prefix":"10.3238","author":[{"given":"Yvonne","family":"Huber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Unverzagt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra Lynen","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Nothacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Moehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"10.3238\/arztebl.m2025.0159_ref1","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, et al.: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229\u201363","DOI":"10.3322\/caac.21834"},{"key":"10.3238\/arztebl.m2025.0159_ref2","unstructured":"Zentrum f\u00fcr Krebsregisterdaten im Robert Koch-Institut: Datenbankabfrage mit Sch\u00e4tzung der Inzidenz, Pr\u00e4valenz und des \u00dcberlebens von Krebs in Deutschland auf Basis der epidemiologischen Landeskrebsregisterdaten. 2023 (updated 07.12.2023. www.krebsdaten.de\/abfrage)."},{"key":"10.3238\/arztebl.m2025.0159_ref3","doi-asserted-by":"crossref","unstructured":"Thrift AP, Wenker TN, El-Serag HB: Global burden of gastric cancer: Epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol 2023; 20: 338\u201349","DOI":"10.1038\/s41571-023-00747-0"},{"key":"10.3238\/arztebl.m2025.0159_ref4","doi-asserted-by":"crossref","unstructured":"Fischbach W, Bornschein J, Hoffmann JC, et al.: Update S2k-guideline helicobacter pylori and gastroduodenal ulcer disease of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS). Z Gastroenterol 2024; 62: 261\u2013321","DOI":"10.1055\/a-2181-2225"},{"key":"10.3238\/arztebl.m2025.0159_ref5","unstructured":"Correa P: Human gastric carcinogenesis: A multistep and multifactorial process\u2014first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res 1992; 52: 6735\u201340."},{"key":"10.3238\/arztebl.m2025.0159_ref6","doi-asserted-by":"crossref","unstructured":"Ford AC, Yuan Y, Moayyedi P: Helicobacter pylori eradication therapy to prevent gastric cancer: Systematic review and meta-analysis. Gut 2020; 69: 2113\u201321","DOI":"10.1136\/gutjnl-2020-320839"},{"key":"10.3238\/arztebl.m2025.0159_ref7","unstructured":"Leitlinienprogramm-Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnostik und Therapie der Adenokarzinome des Magens und \u00f6sophagogastralen \u00dcbergangs, Langversion 3.0, 2025, AWMF-Registernummer 032\u2013009OL. 2025. www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Magenkarzinom\/Version_3\/LL_Magenkarzinom_Langversion_3.0.pdf (last accessed on 3 October 2025)."},{"key":"10.3238\/arztebl.m2025.0159_ref8","doi-asserted-by":"crossref","unstructured":"Chen Q, Liang X, Long X, Yu L, Liu W, Lu H: Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases. Helicobacter 2019; 24: e12563","DOI":"10.1111\/hel.12563"},{"key":"10.3238\/arztebl.m2025.0159_ref9","doi-asserted-by":"crossref","unstructured":"Lansdorp-Vogelaar I, Meester RGS, Laszkowska M, Escudero FA, Ward ZJ, Yeh JM: Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. Best Pract Res Clin Gastroenterol 2021; 50\u201351: 101735","DOI":"10.1016\/j.bpg.2021.101735"},{"key":"10.3238\/arztebl.m2025.0159_ref10","doi-asserted-by":"crossref","unstructured":"Rugge M, Meggio A, Pravadelli C, et al.: Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: A 5-year prospective study of 1755 patients. Gut 2019; 68: 11\u20137","DOI":"10.1136\/gutjnl-2017-314600"},{"key":"10.3238\/arztebl.m2025.0159_ref11","doi-asserted-by":"crossref","unstructured":"Rugge M, Genta RM, Malfertheiner P, et al.: RE.GA.IN.: The real-world Gastritis initiative-updating the updates. Gut 2024; 73: 407\u201341","DOI":"10.1136\/gutjnl-2023-331164"},{"key":"10.3238\/arztebl.m2025.0159_ref12","doi-asserted-by":"crossref","unstructured":"Castellana C, Eusebi LH, Dajti E, et al.: Autoimmune atrophic gastritis: A clinical review. Cancers (Basel) 2024; 16: 1310","DOI":"10.3390\/cancers16071310"},{"key":"10.3238\/arztebl.m2025.0159_ref13","doi-asserted-by":"crossref","unstructured":"Harmon RL, Sugarbaker PH: Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2005; 2: 3","DOI":"10.1186\/1477-7800-2-3"},{"key":"10.3238\/arztebl.m2025.0159_ref14","unstructured":"Institut RK: Krebs in Deutschland f\u00fcr 2019\/2020 2023 (Available from: www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/kid_2023\/kid_2023_c16_magen.pdf?)."},{"key":"10.3238\/arztebl.m2025.0159_ref15","doi-asserted-by":"crossref","unstructured":"Kato M, Nishida T, Yamamoto K, et al.: Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: A multicentre retrospective cohort study by Osaka University ESD study group. Gut 2013; 62: 1425\u201332","DOI":"10.1136\/gutjnl-2011-301647"},{"key":"10.3238\/arztebl.m2025.0159_ref16","doi-asserted-by":"crossref","unstructured":"Facciorusso A, Antonino M, Di Maso M, Muscatiello N: Endoscopic submucosal dissection vs endoscopic mucosal resection for early gastric cancer: A meta-analysis. World J Gastrointest Endosc 2014; 6: 555\u201363","DOI":"10.4253\/wjge.v6.i11.555"},{"key":"10.3238\/arztebl.m2025.0159_ref17","doi-asserted-by":"crossref","unstructured":"Lee JH, Yom CK, Han HS: Comparison of long-term outcomes of laparoscopy-assisted and open distal gastrectomy for early gastric cancer. Surg Endosc 2009; 23: 1759\u201363","DOI":"10.1007\/s00464-008-0198-0"},{"key":"10.3238\/arztebl.m2025.0159_ref18","doi-asserted-by":"crossref","unstructured":"Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11\u201320","DOI":"10.1056\/NEJMoa055531"},{"key":"10.3238\/arztebl.m2025.0159_ref19","doi-asserted-by":"crossref","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al.: Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2\/3 trial. Lancet 2019; 393: 1948\u201357","DOI":"10.1016\/S0140-6736(18)32557-1"},{"key":"10.3238\/arztebl.m2025.0159_ref20","doi-asserted-by":"crossref","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, et al.: Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021; 384: 1191\u2013203","DOI":"10.1056\/NEJMoa2032125"},{"key":"10.3238\/arztebl.m2025.0159_ref21","doi-asserted-by":"crossref","unstructured":"Hoeppner J, Brunner T, Schmoor C, et al.: Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med 2025; 392: 323\u201335","DOI":"10.1056\/NEJMoa2409408"},{"key":"10.3238\/arztebl.m2025.0159_ref22","doi-asserted-by":"crossref","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, et al.: Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med 2025; 393: 217\u201330","DOI":"10.1056\/NEJMoa2503701"},{"key":"10.3238\/arztebl.m2025.0159_ref23","doi-asserted-by":"crossref","unstructured":"Janjigian YY, Ajani JA, Moehler M, et al.: First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 Trial. J Clin Oncol 2024; 42: 2012\u201320","DOI":"10.1200\/JCO.23.01601"},{"key":"10.3238\/arztebl.m2025.0159_ref24","doi-asserted-by":"crossref","unstructured":"Janjigian YY, Moehler MH, Ajani JA, et al.: Nivolumab (NIVO)+ chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma (GC\/GEJC\/EAC): 5-year (y) follow-up results from CheckMate 649. J Clin Oncol 2025; 43: 398\u2013398","DOI":"10.1200\/JCO.2025.43.4_suppl.398"},{"key":"10.3238\/arztebl.m2025.0159_ref25","doi-asserted-by":"crossref","unstructured":"Shitara K, Lordick F, Bang YJ, et al.: Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial. Lancet 2023; 401: 1655\u201368","DOI":"10.1016\/S0140-6736(23)00620-7"},{"key":"10.3238\/arztebl.m2025.0159_ref26","doi-asserted-by":"crossref","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, et al.: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24: 1181\u201395","DOI":"10.1016\/S1470-2045(23)00515-6"},{"key":"10.3238\/arztebl.m2025.0159_ref27","doi-asserted-by":"crossref","unstructured":"Moehler M, Dvorkin M, Boku N, et al.: Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: Results from JAVELIN gastric 100. J Clin Oncol 2021; 39: 966\u201377","DOI":"10.1200\/JCO.20.00892"},{"key":"10.3238\/arztebl.m2025.0159_ref28","doi-asserted-by":"crossref","unstructured":"Al-Batran SE, Goetze TO, Mueller DW, et al.: The RENAISSANCE (AIO-FLOT5) trial: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction\u2014a phase III trial of the German AIO\/CAO-V\/CAOGI. BMC Cancer 2017; 17: 893","DOI":"10.1186\/s12885-017-3918-9"},{"key":"10.3238\/arztebl.m2025.0159_ref29","doi-asserted-by":"crossref","unstructured":"Moehler M, Xiao H, Blum SI, et al.: Health-related quality of life with nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric\/gastroesophageal junction cancer or esophageal adenocarcinoma from CheckMate 649. J Clin Oncol 2023; 41: 5388\u201399","DOI":"10.1200\/JCO.23.00170"},{"key":"10.3238\/arztebl.m2025.0159_ref30","doi-asserted-by":"crossref","unstructured":"Cruz-Correa M, Xu RH, Moehler M, et al.: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: Patient-reported outcomes in the RATIONALE-305 study. Curr Med Res Opin 2025: 41: 1007\u201316","DOI":"10.1080\/03007995.2025.2501588"},{"key":"10.3238\/arztebl.m2025.0159_ref31","doi-asserted-by":"crossref","unstructured":"Wagner AD, Syn NL, Moehler M, et al.: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2017; 8: CD004064","DOI":"10.1002\/14651858.CD004064.pub4"},{"key":"10.3238\/arztebl.m2025.0159_ref32","doi-asserted-by":"crossref","unstructured":"Waidmann O: Perspektiven der Onkologie: Tumoren des Gastrointestinaltrakts: Chemoimmunotherapien \u2013 Nebenwirkungen im Griff. Dtsch Arztebl 2023; 120: [6]","DOI":"10.3238\/PersOnko.2023.10.20.01"},{"key":"10.3238\/arztebl.m2025.0159_ref33","doi-asserted-by":"crossref","unstructured":"Shitara K, Shah MA, Lordick F, et al.: Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma. N Engl J Med 2024; 391: 1159\u201362","DOI":"10.1056\/NEJMc2409512"},{"key":"10.3238\/arztebl.m2025.0159_ref34","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). Palliativmedizin f\u00fcr Patienten mit einer nicht-heilbaren Krebserkrankung, Langversion 2.2. 2020. www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Palliativmedizin\/Version_2\/LL_Palliativmedizin_Langversion_2.2.pdf (last accessed on 3 October 2024)."},{"key":"10.3238\/arztebl.m2025.0159_ref35","doi-asserted-by":"crossref","unstructured":"Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D: Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl 5): v38\u2013v49","DOI":"10.1093\/annonc\/mdw350"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:29:36Z","timestamp":1768548576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":35,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2025.0159","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}